Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.


Search All Patents:



  This Patent May Be For Sale or Lease. Contact Us

  Is This Your Patent? Claim This Patent Now.



Register or Login To Download This Patent As A PDF




United States Patent D835,783
Smith ,   et al. December 11, 2018

Implant placement guide

Claims


CLAIM The ornamental design for an implant placement guide, as shown and described.
Inventors: Smith; Jay S. (Wellesley Hills, MA), Cole; Michael R. (Stratham, NH), Whitson; Amy K. (Columbus, OH)
Applicant:
Name City State Country Type

Intarcia Therapeutics, Inc.

Boston

MA

US
Assignee: Intarcia Therapeutics, Inc. (Boston, MA)
Appl. No.: D/604,792
Filed: May 19, 2017

Related U.S. Patent Documents

Application NumberFiling DatePatent NumberIssue Date
29566823Jun 2, 2016

Current U.S. Class: D24/140; D24/133
Current International Class: 2402
Field of Search: ;D24/140,231,133,146,147,155,169,141

References Cited [Referenced By]

U.S. Patent Documents
1655158 January 1928 Muir
2110208 March 1938 Eggert
2168437 August 1939 Buercklin
2531724 November 1950 Cevasco
2643653 June 1953 Heidrich
D179537 January 1957 Floyd
3016895 January 1962 Sein
3025991 March 1962 Gillon
3122162 February 1964 Sands
3523906 August 1970 Vrancken et al.
3538916 November 1970 Groff et al.
3620216 November 1971 Szymanski
3625214 December 1971 Higuchi
3632768 January 1972 Bergy et al.
3669104 June 1972 Wyatt et al.
3691090 September 1972 Kitajima et al.
D226915 May 1973 Huggins
3732865 May 1973 Higuchi et al.
3737337 June 1973 Schnoring et al.
3766915 October 1973 Rychlik
3773919 November 1973 Boswell et al.
3797492 March 1974 Place
3869549 March 1975 Geller
3891570 June 1975 Fukushima et al.
D236035 July 1975 Ciencewicki
3960757 June 1976 Morishita et al.
3987790 October 1976 Eckenhoff et al.
3995631 December 1976 Higuchi et al.
3995632 December 1976 Nakano et al.
4008719 February 1977 Theeuwes et al.
4034756 July 1977 Higuchi et al.
4078060 March 1978 Benson et al.
4105030 August 1978 Kercso
4111201 September 1978 Theeuwes
4111202 September 1978 Theeuwes
4111203 September 1978 Theeuwes
4203439 May 1980 Theeuwes
4211771 July 1980 Witkowski et al.
4221862 September 1980 Naito et al.
4223674 September 1980 Fluent et al.
4243030 January 1981 Lynch et al.
D258837 April 1981 Spranger et al.
D259458 June 1981 Fuller
4305927 December 1981 Theeuwes et al.
4310516 January 1982 Chang et al.
4340054 July 1982 Michaels
4350271 September 1982 Eckenhoff
4373527 February 1983 Fischell
4376118 March 1983 Daher et al.
4384975 May 1983 Fong
4389330 June 1983 Tice et al.
D271990 December 1983 Lyne
4439196 March 1984 Higuchi
4444498 April 1984 Heinemann
4451253 May 1984 Harman
4455143 June 1984 Theeuwes et al.
4455145 June 1984 Theeuwes
4474572 October 1984 McNaughton et al.
4530840 July 1985 Tice et al.
4552561 November 1985 Eckenhoff et al.
4588614 May 1986 Lauchenauer
4594108 June 1986 Greminger, Jr. et al.
4597753 July 1986 Turley
4609374 September 1986 Ayer
4639244 January 1987 Rizk et al.
4655462 April 1987 Balsells
4673405 June 1987 Guittard et al.
4675184 June 1987 Hasegawa et al.
4695623 September 1987 Stabinsky
4727138 February 1988 Goeddel et al.
4734284 March 1988 Terada et al.
4737437 April 1988 Gutsell, Jr. et al.
4743449 May 1988 Yoshida et al.
4753651 June 1988 Eckenhoff
4762791 August 1988 Goeddel et al.
4765989 August 1988 Wong et al.
4783337 November 1988 Wong et al.
4818517 April 1989 Kwee et al.
4820267 April 1989 Harman
4820638 April 1989 Swetly et al.
4826144 May 1989 Balsells
4830344 May 1989 Balsells
4834708 May 1989 Pillari
4840896 June 1989 Reddy et al.
4845196 July 1989 Cowling
4847079 July 1989 Kwan
4851228 July 1989 Zentner et al.
4865845 September 1989 Eckenhoff et al.
4871094 October 1989 Gall et al.
4873080 October 1989 Brickl et al.
4874388 October 1989 Wong et al.
4876781 October 1989 Balsells
4882166 November 1989 Graham et al.
4885166 December 1989 Meyer et al.
4886668 December 1989 Haslam et al.
4892778 January 1990 Theeuwes et al.
4893795 January 1990 Balsells
4897471 January 1990 Stabinsky
4907788 March 1990 Balsells
4915366 April 1990 Balsells
4915949 April 1990 Wong et al.
4915954 April 1990 Ayer et al.
4917887 April 1990 Hauptmann et al.
4917895 April 1990 Lee et al.
4923805 May 1990 Reddy et al.
4927687 May 1990 Nuwayser
4929554 May 1990 Goeddel et al.
4931285 June 1990 Edgren et al.
4934666 June 1990 Balsells
4940465 July 1990 Theeuwes et al.
4940588 July 1990 Sparks et al.
4952402 August 1990 Sparks et al.
4957119 September 1990 de Nijs
4961253 October 1990 Balsells
4964204 October 1990 Balsells
4969884 November 1990 Yum
4974821 December 1990 Balsells
4976966 December 1990 Theeuwes et al.
4994028 February 1991 Leonard et al.
5004689 April 1991 Fiers et al.
5006346 April 1991 Theeuwes et al.
5019382 May 1991 Cummins, Jr.
5019400 May 1991 Gombotz et al.
5023088 June 1991 Wong et al.
5024842 June 1991 Edgren et al.
5030216 July 1991 Theeuwes et al.
5034229 July 1991 Magruder et al.
5053014 October 1991 Van Heugten
5057318 October 1991 Magruder et al.
5059423 October 1991 Magruder et al.
5066436 November 1991 Komen et al.
5071642 December 1991 Lahr et al.
5072070 December 1991 Balsells
5079388 January 1992 Balsells
5090962 February 1992 Landry et al.
5091188 February 1992 Haynes
5108078 April 1992 Balsells
5110596 May 1992 Magruder et al.
5112614 May 1992 Magruder et al.
5113938 May 1992 Clayton
5117066 May 1992 Balsells
D326718 June 1992 Maxwell
5118666 June 1992 Habener
5120306 June 1992 Gosselin
5120712 June 1992 Habener
5120832 June 1992 Goeddel et al.
5122128 June 1992 Cardinal et al.
5122377 June 1992 Miller
5126142 June 1992 Ayer et al.
5126147 June 1992 Silvestri et al.
5134244 July 1992 Balsells
5137727 August 1992 Eckenhoff
D329278 September 1992 Gallup
5147295 September 1992 Stewart
5151093 September 1992 Theeuwes et al.
5160122 November 1992 Balsells
5160743 November 1992 Edgren et al.
5161806 November 1992 Balsells
5180591 January 1993 Margruder et al.
5190765 March 1993 Jao et al.
5192273 March 1993 Bierman
5203849 April 1993 Balsells
5204108 April 1993 Illum
5207752 May 1993 Sorensen et al.
5209746 May 1993 Balaban et al.
5213809 May 1993 Wright et al.
5213810 May 1993 Steber
5219572 June 1993 Sivaramakrishnan
5221278 June 1993 Linkwitz et al.
5223265 June 1993 Wong
5225205 July 1993 Orsolini
5231176 July 1993 Goeddel et al.
5234424 August 1993 Yum et al.
5234692 August 1993 Magruder et al.
5234693 August 1993 Magruder et al.
5234695 August 1993 Hobbs et al.
5250026 October 1993 Ehrlich et al.
5252338 October 1993 Jao et al.
5260069 November 1993 Chen
D342855 January 1994 Butler, II
5276926 January 1994 Lopez
5278151 January 1994 Korb et al.
5279544 January 1994 Gross et al.
5279554 January 1994 Turley
5279555 January 1994 Lifshey
5279608 January 1994 Cherif Cheikh
5284655 February 1994 Bogdansky et al.
5288501 February 1994 Nurnberg et al.
5288502 February 1994 Mcginity et al.
5290271 March 1994 Jemberg
5300079 April 1994 Niezink et al.
5300302 April 1994 Tachon et al.
5308348 May 1994 Balaban et al.
5312335 May 1994 McKinnon et al.
5312389 May 1994 Theeuwes et al.
5312390 May 1994 Wong
5318558 June 1994 Linkwitz et al.
5318780 June 1994 Viegas et al.
5320616 June 1994 Magndu et al.
5324280 June 1994 Wong et al.
5336057 August 1994 Fukuda et al.
5336505 August 1994 Ng et al.
5348544 September 1994 Sweeney et al.
5352662 October 1994 Brooks et al.
5368588 November 1994 Bettinger
5368863 November 1994 Eckenhoff et al.
5371089 December 1994 Rattan
5374620 December 1994 Clark et al.
5385738 January 1995 Yamahira et al.
5385887 January 1995 Yim et al.
5395319 March 1995 Hirsch et al.
5407609 April 1995 Tice et al.
D358644 May 1995 Park
5411951 May 1995 Mitchell
5413572 May 1995 Wong et al.
5413672 May 1995 Hirotsuji et al.
5424286 June 1995 Eng
5428024 June 1995 Chu et al.
5429602 July 1995 Hauser
5439688 August 1995 Orson et al.
5443459 August 1995 Wong et al.
5445829 August 1995 Paradissis et al.
5456679 October 1995 Balaban et al.
5458888 October 1995 Chen
5464929 November 1995 Bezwada et al.
5472708 December 1995 Chen
5478564 December 1995 Wantier et al.
5484403 January 1996 Yoakum et al.
5486365 January 1996 Takado et al.
5498255 March 1996 Wong et al.
5511355 April 1996 Dingler
5512293 April 1996 Landrau et al.
5512549 April 1996 Chen et al.
5514110 May 1996 Teh
5529914 June 1996 Hubbell et al.
5531736 July 1996 Wong et al.
5540665 July 1996 Mercado et al.
5540912 July 1996 Roorda et al.
5541172 July 1996 Labrie et al.
5542682 August 1996 Goldstein et al.
5543156 August 1996 Roorda et al.
5545618 August 1996 Buckley et al.
5556642 September 1996 Kobayashi et al.
5557318 September 1996 Gabriel
5558637 September 1996 Allonen et al.
5569289 October 1996 Yoon
5571525 November 1996 Roorda et al.
5574008 November 1996 Johnson et al.
5574137 November 1996 Gray et al.
5580578 December 1996 Oshlack et al.
5589167 December 1996 Cleland et al.
5595751 January 1997 Bezwada
5595759 January 1997 Wright et al.
5597579 January 1997 Bezwada et al.
5602010 February 1997 Hauptmann et al.
5605688 February 1997 Himmler et al.
5607687 March 1997 Bezwada et al.
5609885 March 1997 Rivera et al.
5613954 March 1997 Nelson et al.
5614221 March 1997 Fjellstrom
5614492 March 1997 Habener
5618552 April 1997 Bezwada et al.
5620698 April 1997 Bezwada et al.
5620705 April 1997 Dong et al.
5630796 May 1997 Bellhouse et al.
5633011 May 1997 Dong et al.
5635213 June 1997 Nystrom et al.
5639477 June 1997 Maruyama et al.
5639640 June 1997 Reddy et al.
5645850 July 1997 Bezwada et al.
5648088 July 1997 Bezwada et al.
5650173 July 1997 Ramstack et al.
5654008 August 1997 Herbert et al.
5654010 August 1997 Johnson et al.
5656297 August 1997 Bernstein et al.
5656299 August 1997 Kino et al.
5658593 August 1997 Orly et al.
5660847 August 1997 Magruder et al.
5660858 August 1997 Parikh et al.
5660861 August 1997 Jao et al.
5667808 September 1997 Johnson et al.
5668170 September 1997 Gyory
5672549 September 1997 Minami et al.
5676942 October 1997 Testa et al.
5686097 November 1997 Taskovich et al.
5688801 November 1997 Mesens et al.
5690925 November 1997 Gray et al.
5690952 November 1997 Magruder et al.
5695463 December 1997 Cherif-Cheikh
5697113 December 1997 Shatz
5697914 December 1997 Brimhall
5698213 December 1997 Jamiolkowski et al.
5700486 December 1997 Canal et al.
5700583 December 1997 Jamiolkowski et al.
5703200 December 1997 Bezwada et al.
5707644 January 1998 Illum
5711967 January 1998 Juch
5713847 February 1998 Howard, III et al.
5718922 February 1998 Herrero-Vanrell
5725497 March 1998 Woodruff et al.
5728088 March 1998 Margruder et al.
5728396 March 1998 Peery et al.
5733572 March 1998 Unger et al.
5736159 April 1998 Chen et al.
5738845 April 1998 Imakawa
5747058 May 1998 Tipton et al.
5756450 May 1998 Lorenz et al.
5767251 June 1998 Reddy et al.
5770231 June 1998 Mesens et al.
5782396 July 1998 Mastri et al.
5792477 August 1998 Rickey et al.
5795591 August 1998 Lee et al.
5795779 August 1998 McCormick et al.
5807876 September 1998 Armistead et al.
5810769 September 1998 Schlegel et al.
5814323 September 1998 Lyle
D399821 October 1998 Tyneski
5817129 October 1998 Labrecque et al.
5827297 October 1998 Boudjema
5830501 November 1998 Dong et al.
5836935 November 1998 Ashton et al.
5843891 December 1998 Sherman
5844017 December 1998 Jamiolkowski et al.
5851451 December 1998 Takechi et al.
5858746 January 1999 Hubbell et al.
5859150 January 1999 Jamiolkowski et al.
5861166 January 1999 Eckenhoff
5871770 February 1999 Margruder et al.
5871778 February 1999 Kino et al.
5874388 February 1999 Hsu
5876746 March 1999 Jona et al.
5882676 March 1999 Lee et al.
D408917 April 1999 Hacker
5904935 May 1999 Eckenhoff et al.
5906599 May 1999 Kaldany
5906816 May 1999 Soos et al.
5906830 May 1999 Farinas et al.
5908621 June 1999 Glue et al.
5916598 June 1999 Rickey et al.
5922253 July 1999 Herbert et al.
5928666 July 1999 Farinas et al.
5932547 August 1999 Stevenson et al.
5938654 August 1999 Wong et al.
5939286 August 1999 Johnson et al.
5942223 August 1999 Bazer et al.
5942253 August 1999 Gombotz et al.
5945126 August 1999 Thanoo et al.
5948430 September 1999 Zerbe et al.
5951521 September 1999 Mastrototaro et al.
5958909 September 1999 Habener
D415073 October 1999 Meehan
5962023 October 1999 Jamiolkowski et al.
5965168 October 1999 Mesens et al.
5972370 October 1999 Eckenhoff et al.
5972373 October 1999 Yajima et al.
5976109 November 1999 Heruth
5980945 November 1999 Ruiz
5981719 November 1999 Woiszwillo et al.
5984890 November 1999 Gast et al.
5985305 November 1999 Peery et al.
5989463 November 1999 Tracy et al.
5997527 December 1999 Gumucio et al.
5997902 December 1999 Maruyama et al.
6007805 December 1999 Foster et al.
6017545 January 2000 Modi
6022561 February 2000 Carlsson et al.
6023802 February 2000 King
6029361 February 2000 Newman
6053927 April 2000 Hamas
6060450 May 2000 Soos et al.
6069133 May 2000 Carlo et al.
6074377 June 2000 Sanfilippo, II
6074660 June 2000 Jamiolkowski et al.
6074673 June 2000 Guillen
6100346 August 2000 Jamiolkowski et al.
6110503 August 2000 Rickey et al.
D430671 September 2000 Shute
6113938 September 2000 Chen et al.
6113947 September 2000 Cleland et al.
6120787 September 2000 Gustafsson et al.
6124261 September 2000 Stevenson et al.
6124281 September 2000 Lewis et al.
6127520 October 2000 Ueda et al.
6129761 October 2000 Hubbell
6130200 October 2000 Brodbeck et al.
6132420 October 2000 Dionne et al.
6133249 October 2000 Hills
6133429 October 2000 Davis et al.
6146139 November 2000 Harrison, III
6147168 November 2000 Jamiolkowski et al.
6156331 December 2000 Peery et al.
6172046 January 2001 Albrecht
6174547 January 2001 Dong et al.
6177096 January 2001 Zerbe et al.
6183461 February 2001 Matsuura et al.
6187095 February 2001 Labrecque et al.
6190350 February 2001 Davis et al.
6190700 February 2001 Okada et al.
6190702 February 2001 Takada et al.
6191102 February 2001 DiMarchi et al.
6204022 March 2001 Johnson et al.
6217893 April 2001 Pellet et al.
6217906 April 2001 Gumucio et al.
6217908 April 2001 Mathiowitz et al.
6218431 April 2001 Schoen et al.
6224894 May 2001 Jamiolkowski et al.
6235712 May 2001 Stevenson et al.
6245349 June 2001 Yiv et al.
6245357 June 2001 Edgren et al.
6248112 June 2001 Gambale et al.
6251435 June 2001 Jamiolkowski et al.
D445975 July 2001 Stratford
6258377 July 2001 New et al.
6261584 July 2001 Peery et al.
6268343 July 2001 Knudsen et al.
6270700 August 2001 Ignatious
6270787 August 2001 Ayer
6277413 August 2001 Sankaram
6283949 September 2001 Roorda
6284264 September 2001 Zerbe et al.
6284727 September 2001 Kim et al.
6287295 September 2001 Chen et al.
6284725 December 2001 Coolidge et al.
6329336 December 2001 Bridon et al.
6331311 December 2001 Brodbeck et al.
6372218 April 2002 Cummins, Jr.
6372256 April 2002 Jamiolkowski et al.
6375978 April 2002 Kleiner et al.
D456776 May 2002 Lindekugel
6395282 May 2002 Kende et al.
6395292 May 2002 Peery et al.
6402716 June 2002 Ryoo et al.
6403655 June 2002 Bezwada et al.
6419952 July 2002 Wong et al.
6428517 August 2002 Hochman et al.
6433144 August 2002 Morris et al.
6436091 August 2002 Harper et al.
6447522 September 2002 Garnbale et al.
6451974 September 2002 Hansen
6458385 October 2002 Jamiolkowski et al.
6458387 October 2002 Scott et al.
6458924 October 2002 Knudsen et al.
6461605 October 2002 Cutler et al.
6464688 October 2002 Harper et al.
6468961 October 2002 Brodbeck et al.
6471688 October 2002 Harper et al.
6472512 October 2002 LaFleur et al.
6478768 November 2002 Kneer
6485706 November 2002 McCoy et al.
6495164 December 2002 Ramstack et al.
6506724 January 2003 Hiles et al.
6508808 January 2003 Carr et al.
6514500 February 2003 Bridon et al.
6514517 February 2003 Jamilolkowski et al.
6524305 February 2003 Peterson et al.
6528093 March 2003 Kamei et al.
6528486 March 2003 Larsen et al.
D472896 April 2003 Peiker
6541021 April 2003 Johnson et al.
6544239 April 2003 Kinsey et al.
6544252 April 2003 Theeuwes et al.
6547250 April 2003 Noble
6551613 April 2003 Dong et al.
6569420 May 2003 Chen et al.
6572890 June 2003 Faour et al.
6579851 June 2003 Goeke et al.
6589157 July 2003 Fontayne et al.
6592508 July 2003 Ravins et al.
6592887 July 2003 Zerbe et al.
6593295 July 2003 Bridon et al.
6607529 August 2003 Jones et al.
6626863 September 2003 Berler
6635268 October 2003 Peery et al.
6645192 November 2003 Kenison et al.
6667061 December 2003 Rarnstack et al.
6670368 December 2003 Breault et al.
6673767 January 2004 Brodbeck et al.
6682522 January 2004 Carr et al.
6703225 March 2004 Kojima et al.
6703359 March 2004 Young et al.
6706689 March 2004 Coolidge et al.
6709671 March 2004 Zerbe et al.
6720407 April 2004 Hughes et al.
6730328 May 2004 Maskiwicz et al.
6767887 July 2004 Hoffmann et al.
6821949 November 2004 Bridon et al.
6833256 December 2004 Pontzer et al.
6835194 December 2004 Johnson et al.
6840931 January 2005 Peterson et al.
6849708 February 2005 Habener
6849714 February 2005 Bridon et al.
6858576 February 2005 Young et al.
6872700 March 2005 Young et al.
6875748 April 2005 Manthorpe et al.
6887470 May 2005 Bridon et al.
6887849 May 2005 Bridon et al.
6899887 May 2005 Ayer
6899898 May 2005 Albayrak
6902744 June 2005 Kolterman et al.
6903186 June 2005 Dong
6913767 July 2005 Cleland et al.
6923800 August 2005 Chen et al.
6924264 August 2005 Prickett et al.
6939556 September 2005 Lautenbach
6956026 October 2005 Beeley et al.
6960192 November 2005 Flaherty et al.
6969702 November 2005 Bertilsson et al.
6976981 December 2005 Ayer
6989366 January 2006 Beeley et al.
6992065 January 2006 Okumu
6997922 February 2006 Theeuwes et al.
7008439 March 2006 Janzen et al.
7014636 March 2006 Gilbert
7022674 April 2006 DeFelippis et al.
7041646 May 2006 Pan et al.
7074423 July 2006 Fereira et al.
7084243 August 2006 Glaesner et al.
7101567 September 2006 Sano et al.
7101843 September 2006 Glaesner et al.
7112335 September 2006 Lautenbach
7115569 October 2006 Beeley et al.
7138375 November 2006 Beeley et al.
7138486 November 2006 Habener
7141547 November 2006 Rosen et al.
7144863 December 2006 DeFelippis et al.
7153825 December 2006 Young et al.
7157555 January 2007 Beeley et al.
7163688 January 2007 Peery et al.
7163697 January 2007 Hanes et al.
7199217 April 2007 DiMarchi et al.
7205409 April 2007 Pei et al.
7207982 April 2007 Dionne et al.
7214206 May 2007 Rue et al.
7241457 July 2007 Chen et al.
7258869 August 2007 Berry et al.
D555589 November 2007 Hussaini
7297761 November 2007 Beeley et al.
7316680 January 2008 Gilbert
7393827 July 2008 Nadler
7407499 August 2008 Trautman
7442682 October 2008 Kitaura et al.
7456254 November 2008 Wright et al.
7459432 December 2008 Cowley et al.
7521423 April 2009 Young et al.
7563871 July 2009 Wright et al.
7589169 September 2009 Bolotin
7604647 October 2009 Chen
7612176 November 2009 Wright et al.
7632256 December 2009 Mosler et al.
7635463 December 2009 Bolotin et al.
D608447 January 2010 Meyer
7655254 February 2010 Dennis et al.
7655257 February 2010 Peery et al.
7666835 February 2010 Bloom et al.
7682356 March 2010 Alessi et al.
7727519 June 2010 Moran
7731947 June 2010 Eliaz et al.
7736665 June 2010 Patel et al.
7741269 June 2010 Young et al.
7766924 August 2010 Bombard et al.
7790140 September 2010 Bolotin
7825091 November 2010 Bloom et al.
7829109 November 2010 Chen et al.
7833543 November 2010 Gibson et al.
7879028 February 2011 Alessi et al.
7879794 April 2011 Berry et al.
7919109 April 2011 Berry et al.
D638478 May 2011 Block
7928065 June 2011 Rohloff et al.
7964183 June 2011 Eliaz et al.
8039432 October 2011 Bridon et al.
7959938 November 2011 Lautenbach et al.
8048438 November 2011 Berry et al.
8052996 November 2011 Lautenbach et al.
8058233 November 2011 Cowley et al.
8101576 January 2012 Bloom
8114430 February 2012 Rohloff et al.
8114437 February 2012 Rohloff et al.
8158150 April 2012 Lautenbach et al.
8173150 May 2012 Berry et al.
8202836 June 2012 Moore et al.
8206745 June 2012 Rohloff et al.
8211467 July 2012 Rohloff et al.
8217001 July 2012 Cowley et al.
8231859 July 2012 Bolotin et al.
8251946 August 2012 Bardy
8257682 September 2012 Bolotin et al.
8257691 September 2012 Eliaz et al.
8263545 September 2012 Bloom
8263736 September 2012 Berry
8268341 September 2012 Berry
8273365 September 2012 Lautenbach et al.
8273713 September 2012 Pittner et al.
D669589 October 2012 Delaey
8277776 October 2012 Bolotin et al.
8278267 October 2012 Weyer et al.
8288338 October 2012 Alessi et al.
8298561 October 2012 Alessi et al.
8299025 October 2012 Alessi et al.
8343140 January 2013 Alessi et al.
8367095 February 2013 Lautenbach et al.
8372424 February 2013 Berry et al.
D678889 March 2013 Chiu
8398967 March 2013 Eliaz et al.
8440226 May 2013 Rohloff et al.
8454552 June 2013 Bardy
8460694 June 2013 Rohloff et al.
8470353 June 2013 Lautenbach et al.
8556861 October 2013 Tsals
8722037 May 2014 Veenstra et al.
8747412 June 2014 Bae et al.
8801700 August 2014 Alessi et al.
8815802 August 2014 Kalthoff et al.
8845726 September 2014 Tebbe
8858621 October 2014 Oba
8865202 October 2014 Zerbe et al.
8888745 November 2014 Van Der Graaf et al.
8926595 January 2015 Alessi et al.
8940316 January 2015 Alessi et al.
8992961 March 2015 Berry et al.
8992962 March 2015 Lautenbach et al.
9044209 June 2015 Dayton et al.
9078900 July 2015 Kuzma et al.
9095553 August 2015 Rohloff et al.
9241722 January 2016 Yu
D750764 March 2016 DeSocio
9332995 May 2016 Russo
9526763 December 2016 Rohloff et al.
9539200 January 2017 Lautenbach
9572889 February 2017 Alessi et al.
D789539 June 2017 Kleiner
D789540 June 2017 Gyorgy
9682127 June 2017 Alessi et al.
RE46577 October 2017 Collins
D805199 December 2017 Chen
D810289 February 2018 Jutila
9889085 February 2018 Alessi et al.
9931133 April 2018 Mirza
D816843 May 2018 Lewis
D819820 June 2018 Radau
2001/0012511 August 2001 Bezwada et al.
2001/0021377 September 2001 Jamiolkowski et al.
2001/0021822 September 2001 Ayer
2001/0022974 September 2001 Ayer
2001/0026793 October 2001 Jamiolkowski et al.
2001/0027311 October 2001 Chen et al.
2001/0031940 October 2001 Loos
2001/0031790 November 2001 Beisswenger
2001/0036472 November 2001 Wong et al.
2001/0040326 November 2001 Balczun
2002/0001631 January 2002 Okumu
2002/0004481 January 2002 Cleland et al.
2002/0012818 January 2002 Ruppi et al.
2002/0034532 March 2002 Brodbeck et al.
2002/0037309 March 2002 Jaworowicz et al.
2002/0048600 April 2002 Bhatt et al.
2002/0077599 June 2002 Wojcik
2002/0098180 July 2002 Lei
2002/0136848 September 2002 Yoshii et al.
2002/0137666 September 2002 Beeley et al.
2002/0141985 October 2002 Pittner et al.
2002/0197185 December 2002 Jamiolkowski et al.
2002/0197235 December 2002 Moran
2003/0007992 January 2003 Gibson et al.
2003/0032947 February 2003 Harper et al.
2003/0040699 February 2003 Talling
2003/0044467 March 2003 Brodbeck et al.
2003/0045454 March 2003 Okumu et al.
2003/0059376 March 2003 Libbey et al.
2003/0059471 March 2003 Compton et al.
2003/0060425 March 2003 Ahlem et al.
2003/0078618 April 2003 Fey et al.
2003/0097121 June 2003 Babcock et al.
2003/0104063 June 2003 Babcock et al.
2003/0108608 June 2003 Berry et al.
2003/0108609 June 2003 Berry et al.
2003/0113380 June 2003 Ramstack et al.
2003/0114837 June 2003 Peterson et al.
2003/0118660 June 2003 Rickey et al.
2003/0135153 July 2003 Hagemeier
2003/0138403 July 2003 Drustrup
2003/0138491 July 2003 Tracy et al.
2003/0157178 August 2003 Chen et al.
2003/0170289 September 2003 Chen et al.
2003/0180364 September 2003 Chen et al.
2003/0186858 October 2003 Arentsen
2003/0191099 October 2003 Bohlmann et al.
2003/0211974 November 2003 Brodbeck et al.
2003/0215515 November 2003 Truong-Le et al.
2003/0220617 November 2003 Dickerson
2003/0233101 December 2003 Lubock et al.
2004/0001689 January 2004 Goldsmith et al.
2004/0001889 January 2004 Chen et al.
2004/0002442 January 2004 Pan et al.
2004/0022859 February 2004 Chen et al.
2004/0024068 February 2004 Chen et al.
2004/0024069 February 2004 Chen et al.
2004/0029784 February 2004 Hathaway
2004/0039376 February 2004 Peery et al.
2004/0047888 March 2004 Kenison et al.
2004/0097906 May 2004 Fereira et al.
2004/0101557 May 2004 Gibson et al.
2004/0102762 May 2004 Gilbert
2004/0115236 June 2004 Chan et al.
2004/0142867 July 2004 Oi et al.
2004/0142902 July 2004 Struijker-Boudier
2004/0151753 August 2004 Chen et al.
2004/0157951 August 2004 Wolf
2004/0198654 October 2004 Glaesner et al.
2004/0199140 October 2004 Rue
2004/0209801 October 2004 Brand et al.
2004/0215133 October 2004 Weber et al.
2004/0224903 November 2004 Berry et al.
2004/0225113 November 2004 LaFleur et al.
2004/0243106 December 2004 Ayer
2004/0265273 December 2004 Li et al.
2004/0266683 December 2004 Hathaway et al.
2004/0266692 December 2004 Young et al.
2005/0004557 January 2005 Russell
2005/0008661 January 2005 Fereira et al.
2005/0009742 January 2005 Bertilsson et al.
2005/0010196 January 2005 Fereira et al.
2005/0070883 March 2005 Brown et al.
2005/0079200 April 2005 Rathenow et al.
2005/0079202 April 2005 Chen et al.
2005/0010942 May 2005 Eliaz et al.
2005/0095284 May 2005 Trautman
2005/0101943 May 2005 Ayer et al.
2005/0106214 May 2005 Chen
2005/0112188 May 2005 Eliaz et al.
2005/0118206 June 2005 Luk et al.
2005/0118221 June 2005 Blakely et al.
2005/0131386 June 2005 Freeman et al.
2005/0131389 June 2005 Peterson et al.
2005/0143749 June 2005 Zalenski et al.
2005/0175701 August 2005 Pan et al.
2005/0201980 September 2005 Moran
2005/0215475 September 2005 Ong et al.
2005/0266087 December 2005 Junnarkar et al.
2005/0271702 December 2005 Wright et al.
2005/0276856 December 2005 Fereira et al.
2005/0281879 December 2005 Chen et al.
2006/0013879 January 2006 Brodbeck et al.
2006/0014678 January 2006 Cowley et al.
2006/0030526 February 2006 Liu et al.
2006/0069029 March 2006 Kolterman et al.
2006/0073182 April 2006 Wong et al.
2006/0084604 April 2006 Kitaura et al.
2006/0094652 May 2006 Levy et al.
2006/0094693 May 2006 Aziz et al.
2006/0141040 June 2006 Chen et al.
2006/0142234 June 2006 Chen et al.
2006/0160736 July 2006 Nadler
2006/0178304 August 2006 Juul-Mortensen et al.
2006/0193918 August 2006 Rohloff et al.
2006/0216242 September 2006 Rohloff et al.
2006/0224145 October 2006 Gills
2006/0233841 October 2006 Brodbeck et al.
2006/0246138 November 2006 Rohloff et al.
2006/0251618 November 2006 Dennis et al.
2006/0263433 November 2006 Ayer et al.
2006/0264890 November 2006 Moberg et al.
2006/0280795 December 2006 Penhasi et al.
2006/0293232 December 2006 Levy et al.
2007/0027105 February 2007 Junnarkar et al.
2007/0141102 June 2007 De Graaff et al.
2007/0149011 June 2007 Kent et al.
2007/0166352 July 2007 Wright et al.
2007/0207958 September 2007 Bridon et al.
2007/0248572 October 2007 Moran et al.
2007/0281024 December 2007 Lautenbach et al.
2008/0020016 January 2008 Li et al.
2008/0038316 February 2008 Wong et al.
2008/0064636 March 2008 Bloom et al.
2008/0091176 April 2008 Alessi et al.
2008/0110515 May 2008 Angelosanto et al.
2008/0112994 May 2008 Junnarkar
2008/0200383 August 2008 Jennings et al.
2008/0207512 August 2008 Roth et al.
2008/0208194 August 2008 Bickenbach
2008/0226625 September 2008 Berry et al.
2008/0226689 September 2008 Berry et al.
2008/0260838 October 2008 Hokenson et al.
2008/0260840 October 2008 Alessi et al.
2008/0269725 October 2008 Deem et al.
2008/0312157 December 2008 Levy et al.
2009/0012463 January 2009 Beelen et al.
2009/0022727 January 2009 Houston et al.
2009/0036364 February 2009 Levy et al.
2009/0042781 February 2009 Petersen et al.
2009/0074734 March 2009 Rottiers
2009/0087408 April 2009 Berry et al.
2009/0125030 May 2009 Tebbe
2009/0156474 June 2009 Roth et al.
2009/0163447 June 2009 Maggio
2009/0186817 July 2009 Ghosh et al.
2009/0202481 August 2009 Li et al.
2009/0202608 August 2009 Alessi et al.
2009/0209460 August 2009 Young et al.
2009/0210019 August 2009 Kim et al.
2009/0215694 August 2009 Kolterman et al.
2009/0234392 September 2009 Dziedzic
2009/0247463 October 2009 Wright et al.
2009/0254143 October 2009 Tweden et al.
2009/0286723 November 2009 Levy et al.
2009/0312246 December 2009 Baron et al.
2010/0092566 April 2010 Alessi et al.
2010/0094252 April 2010 Wengreen et al.
2010/0105627 April 2010 Salama et al.
2010/0144621 June 2010 Kim et al.
2010/0185184 July 2010 Alessi et al.
2010/0297209 November 2010 Rohloff et al.
2010/0298807 November 2010 Jansen et al.
2010/0331868 December 2010 Bardy
2011/0076317 March 2011 Alessi et al.
2011/0104111 May 2011 Rohloff et al.
2011/0152181 June 2011 Alsina-Fernandez et al.
2011/0152182 June 2011 Alsina-Fernandez et al.
2011/0160708 June 2011 Berry et al.
2011/0166554 July 2011 Alessi et al.
2011/0264077 October 2011 Rohloff et al.
2011/0306549 December 2011 Tatarkiewicz et al.
2012/0178687 July 2012 Alessi et al.
2012/0208755 August 2012 Leung
2012/0265232 October 2012 Surbone
2012/0303045 November 2012 Cooper et al.
2013/0030417 January 2013 Alessi
2013/0034210 February 2013 Rohloff et al.
2013/0052237 February 2013 Eliaz et al.
2013/0296661 November 2013 Bornzin et al.
2013/0324977 December 2013 Vanderpool
2014/0058409 February 2014 Bratlie
2014/0148837 May 2014 Levitan
2014/0163057 June 2014 Patel et al.
2014/0236162 August 2014 Barongan
2014/0324067 October 2014 Emken
2014/0378900 December 2014 Alessi et al.
2015/0111818 January 2015 Alessi et al.
2015/0057227 February 2015 Leung
2015/0231062 August 2015 Lautenbach et al.
2015/0231256 August 2015 Berry et al.
2015/0297509 October 2015 Schwarz
2015/0359553 December 2015 Harnisch
2016/0022582 January 2016 Alessi et al.
2016/0030337 February 2016 Kuzma
2016/0354115 December 2016 Smith et al.
2016/0354305 December 2016 Alessi et al.
2017/0056476 March 2017 Rohloff et al.
2017/0079906 March 2017 Alessi et al.
2017/0119854 May 2017 Alessi et al.
2017/0119855 May 2017 Berry et al.
2017/0181964 June 2017 Lautenbach et al.
2017/0252409 September 2017 Leung
2017/0273706 September 2017 Mirza
2017/0319470 November 2017 Eliaz et al.
2017/0319662 November 2017 Berry et al.
2017/0348392 December 2017 Rohloff et al.
2017/0368145 December 2017 Alessi et al.
2018/0009871 January 2018 Blackwell et al.
2018/0193059 July 2018 Bae
Foreign Patent Documents
000000635692 Sep 1936 DE
0079405 May 1983 EP
0254394 Jan 1988 EP
0295411 Dec 1988 EP
0304107 Feb 1989 EP
0368339 May 1990 EP
0373867 Jun 1990 EP
0431942 Jun 1991 EP
0486959 May 1992 EP
0497575 Aug 1992 EP
0521586 Jan 1993 EP
0596161 May 1994 EP
0379147 Sep 1994 EP
0627231 Dec 1994 EP
0631794 Jan 1995 EP
0729747 May 1997 EP
0771817 May 1997 EP
0596161 Feb 1998 EP
0841359 May 1998 EP
0767689 Jun 1999 EP
1046399 Oct 2000 EP
1084703 Mar 2001 EP
1300129 Apr 2003 EP
1300173 Apr 2003 EP
1300129 May 2003 EP
1323450 Jul 2003 EP
1600187 Jan 2009 EP
2133073 Dec 2009 EP
2020990 Sep 2010 EP
640907 Jul 1928 FR
2616665 Dec 1988 FR
1049104 Nov 1966 GB
1518683 Jul 1978 GB
2138298 Nov 1986 GB
2501400 Oct 2013 GB
H02124814 May 1990 JP
H07196479 Aug 1995 JP
1997/509346 Sep 1997 JP
9241153 Sep 1997 JP
11-100353 Apr 1999 JP
2006/213727 Aug 2006 JP
8901004 Nov 1990 NL
9000948 Nov 1990 NL
9100160 Aug 1992 NL
9100160 Aug 1992 NL
592113 Aug 2012 NZ
200634060 Oct 2006 TW
WO-1989/003678 May 1989 WO
WO-1990/013285 Nov 1990 WO
WO-1990/013361 Nov 1990 WO
WO-1990/013780 Nov 1990 WO
WO 91/07160 May 1991 WO
WO-1992/019241 Nov 1992 WO
WO 93/06819 Apr 1993 WO
WO 93/06821 Apr 1993 WO
WO 93/008832 May 1993 WO
WO 93/09763 May 1993 WO
WO 93/23083 Nov 1993 WO
WO 94/09743 May 1994 WO
WO-1994/010982 May 1994 WO
WO 94/21262 Sep 1994 WO
WO 95/01167 Jan 1995 WO
WO 95/09006 Apr 1995 WO
WO 95/09007 Apr 1995 WO
WO-1995/013799 May 1995 WO
WO 95/34285 Dec 1995 WO
WO 96/001134 Jan 1996 WO
WO 96/003116 Feb 1996 WO
WO-1996/036317 Nov 1996 WO
WO 96/39142 Dec 1996 WO
WO 96/40049 Dec 1996 WO
WO 96/40139 Dec 1996 WO
WO 96/40355 Dec 1996 WO
WO-1996/040049 Dec 1996 WO
WO 97/15289 May 1997 WO
WO 97/15296 May 1997 WO
WO 97/28181 Aug 1997 WO
WO-1997/031943 Sep 1997 WO
WO-1997/044039 Nov 1997 WO
WO 97/46204 Dec 1997 WO
WO 97/47339 Dec 1997 WO
WO 98/00152 Jan 1998 WO
WO 98/00157 Jan 1998 WO
WO 98/00158 Jan 1998 WO
WO 98/02169 Jan 1998 WO
WO-1997/041837 Feb 1998 WO
WO-1998/007412 Feb 1998 WO
WO 98/13092 Apr 1998 WO
WO 98/16250 Apr 1998 WO
WO 98/17315 Apr 1998 WO
WO 1998/13091 Apr 1998 WO
WO 98/20930 May 1998 WO
WO 98/27960 Jul 1998 WO
WO 98/027962 Jul 1998 WO
WO 98/27963 Jul 1998 WO
WO 98/030231 Jul 1998 WO
WO 98/32463 Jul 1998 WO
WO-1998/030231 Jul 1998 WO
WO 98/42317 Oct 1998 WO
WO 98/47487 Oct 1998 WO
WO 98/51282 Nov 1998 WO
WO 98/58698 Dec 1998 WO
WO 99/03453 Jan 1999 WO
WO 99/04767 Feb 1999 WO
WO 99/004768 Feb 1999 WO
WO-1999/012549 Mar 1999 WO
WO 99/16419 Apr 1999 WO
WO 99/025728 May 1999 WO
WO 99/29306 Jun 1999 WO
WO 99/033446 Jul 1999 WO
WO 99/33449 Jul 1999 WO
WO 99/39700 Aug 1999 WO
WO 99/040788 Aug 1999 WO
WO 99/044659 Sep 1999 WO
WO 99/062501 Dec 1999 WO
WO 99/064061 Dec 1999 WO
WO 00/013663 Mar 2000 WO
WO 00/029206 May 2000 WO
WO 00/038652 Jul 2000 WO
WO 00/039280 Jul 2000 WO
WO 00/040273 Jul 2000 WO
WO 00/041548 Jul 2000 WO
WO 00/045790 Aug 2000 WO
WO 00/054745 Sep 2000 WO
WO-2000/059476 Oct 2000 WO
WO 00/066138 Nov 2000 WO
WO 00/067728 Nov 2000 WO
WO-2000/066087 Nov 2000 WO
WO-2001/019345 Mar 2001 WO
WO 01/28631 Apr 2001 WO
WO-2001/028525 Apr 2001 WO
WO 01/043528 Jun 2001 WO
WO 01/051041 Jul 2001 WO
WO 01/68168 Sep 2001 WO
WO 01/78683 Oct 2001 WO
WO 02/028366 Apr 2002 WO
WO 02/036072 May 2002 WO
WO 02/043800 Jun 2002 WO
WO 02/045752 Jun 2002 WO
WO 02/47716 Jun 2002 WO
WO 02/067895 Sep 2002 WO
WO 02/069983 Sep 2002 WO
WO 02/76344 Oct 2002 WO
WO 02/085428 Oct 2002 WO
WO 03/000230 Jan 2003 WO
WO 03/007981 Jan 2003 WO
WO 03/011892 Feb 2003 WO
WO 03/024357 Mar 2003 WO
WO 03/024503 Mar 2003 WO
WO-2003/020245 Mar 2003 WO
WO 03/030923 Apr 2003 WO
WO 03/041684 May 2003 WO
WO 03/041757 May 2003 WO
WO 03/053400 Jul 2003 WO
WO-2003/066585 Aug 2003 WO
WO 03/072113 Sep 2003 WO
WO 03/072133 Sep 2003 WO
WO 04/002565 Jan 2004 WO
WO 2004/026106 Apr 2004 WO
WO-2004/034975 Apr 2004 WO
WO-2004/035754 Apr 2004 WO
WO-2004/035762 Apr 2004 WO
WO-2004/036186 Apr 2004 WO
WO 04/046338 Jun 2004 WO
WO 04/052336 Jun 2004 WO
WO 04/056338 Jul 2004 WO
WO 04/089335 Oct 2004 WO
WO 2004/089458 Oct 2004 WO
WO-2004/103342 Dec 2004 WO
WO 05/048930 Jun 2005 WO
WO 05/048952 Jun 2005 WO
WO 05/102293 Nov 2005 WO
WO-2005/102293 Nov 2005 WO
WO-2005/110425 Nov 2005 WO
WO 06/017772 Feb 2006 WO
WO 06/023526 Mar 2006 WO
WO 2006/077242 Jul 2006 WO
WO 2006/077250 Jul 2006 WO
WO 06/081279 Aug 2006 WO
WO 06/083761 Aug 2006 WO
WO 06/084139 Aug 2006 WO
WO 06/086727 Aug 2006 WO
WO 06/101815 Sep 2006 WO
WO 06/111169 Oct 2006 WO
WO-2006/131730 Dec 2006 WO
WO 07/024700 Mar 2007 WO
WO 07/056681 May 2007 WO
WO 07/075534 Jul 2007 WO
WO 07/084460 Jul 2007 WO
WO 2007/082889 Jul 2007 WO
WO 07/133778 Nov 2007 WO
WO 07/140416 Dec 2007 WO
WO 08/021133 Feb 2008 WO
WO-2008/041245 Apr 2008 WO
WO 08/061355 May 2008 WO
WO-2008/086086 Jul 2008 WO
WO 08/133908 Nov 2008 WO
WO 08/134425 Nov 2008 WO
WO 09/109927 Sep 2009 WO
WO-2009/143285 Nov 2009 WO
WO 2010/045169 Apr 2010 WO
WO 2013/004983 Jan 2013 WO
WO 2013/184235 Dec 2013 WO

Other References

"Abstracts 2007," Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (XP002538652). cited by applicant .
Jetschmann et al., "Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C," Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454). cited by applicant .
Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME). cited by applicant .
"Implantable infusion pumps: technology poised for takeoff," BBI Newsletter 17(12):209-211 (Dec. 1994). cited by applicant .
"Search Report and Written Opinion" dated Dec. 19, 2008 for PCT/US2008/005235, filed Apr. 22, 2008. cited by applicant .
Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer," J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997). cited by applicant .
Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) .omega.1: evidence that IFN- .omega.1 is a component of human leukocyte IFN," Virology 175(2):410-471 (Apr. 1990). cited by applicant .
Adolf et al., "Antigenic structure of human interferon .omega.1 (Interferon .alpha.11 1): comparison with other human interferons," J. Gen. Virol. 68(6):1669-1676 (Jun. 1987). cited by applicant .
Adolf et al., "Purification and characterization of natural human interferon .omega.1," J. Bio. Chem. 265(16):9290-9295 (Jun. 1990). cited by applicant .
Adolf et al., "Human interferon .omega.1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991). cited by applicant .
ANDRX Pharmaceuticals, LLC, ANDA for Concerta.RTM. Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005). cited by applicant .
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984). cited by applicant .
Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999). cited by applicant .
Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999). cited by applicant .
Aulitzky, "Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama," Journal of Clinical Oncology 7(12):1875-1884 (1989). cited by applicant .
Hauck, "Engineer's Guide to Plastics," Materials Engineering 5(72):38-45 (Jul. 17, 1972). cited by applicant .
Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," Bioconjugate Chemistry 12(2):195-202 (2001). cited by applicant .
Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," J. Pharm. Sci., 85(9):908-914 (1996). cited by applicant .
Bakhtiar et al, "Taking Delivery," Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems). cited by applicant .
Balkwill,F., "Interferons," Lancet 1(8646):1060-1063 (May 1989). cited by applicant .
Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984). cited by applicant .
Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," Hepatology 33(2):419-423 (Feb. 2001). cited by applicant .
Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," Nature 302:716-718 (1983). cited by applicant .
Bell et al, "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995). cited by applicant .
Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," Int. J. Radiat. Biol. 67(1):57-64 (1995). cited by applicant .
Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," Euro. J. Pharm. Sci. 2(4):271-279 (1994). cited by applicant .
Bolinger et al., "Recombinant interferon .gamma. for treatment of chronic granulomatous disease and other disorders," Clin. Pharm. 11(10):834-850 (Oct. 1992). cited by applicant .
Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000). cited by applicant .
Borden et al., "Second-generation interferons for cancer: clinical targets," Semin. Cancer Biol. 10(2):125-144 (Apr. 2000). cited by applicant .
Boue et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN-.omega.1 obtained from Pichia pastoris," J. Interferon & Cytokine Res. 20:677-683 (2000). cited by applicant .
Buckwold et. al. "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006). cited by applicant .
Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence," J. Chem. Physics 104(20):8082-8095 (1996). cited by applicant .
CAS No. 56-81-5 (Nov. 16, 1984). cited by applicant .
Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," Pharm. Tech. 20(1):80-84 (1996). cited by applicant .
Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," Chem. & Physics of Lipids 1(5):445-475 (1967). cited by applicant .
Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998). cited by applicant .
Clark et al., "The diabetic Zucker fatty rat," Proc. Soc. Exp. Biol. 173(1):68-75 (1983). cited by applicant .
Condino-Neto, "Interferon-.gamma. improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," Blood 95(11):3548-3554 (Jun. 2000). cited by applicant .
Darney, "Subdermal progestin implant contraception," Current Opinion in Obstetrics & Gynecology 3:470-476 (1991). cited by applicant .
Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," BioPharm, 2(11):44-51 (1999). cited by applicant .
Dash et al., "Therapeutic applications of implantable drug delivery systems," Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998). cited by applicant .
Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ). cited by applicant .
Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002). cited by applicant .
Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," J. Am. Chem. Soc. 116(21):9420-9422 (1994). cited by applicant .
Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose .alpha.-2B interferon plus ribavirin for 6 or 12 months," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569). cited by applicant .
Dorr et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days," J. Interferon Res. 8:717-725 (1988). cited by applicant .
Uhlig et al., "The electro-osmotic actuation of implantable insulin micropumps," J. Biomed. Materials Res. 17:931-943 (1983). cited by applicant .
Efendic et al., "Overview of incretin hormones," Horm. Metab. Res., 36(11-12):742-746 (2004). cited by applicant .
Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," Life Sci., 55(8):629-634 (1994). cited by applicant .
Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-.alpha. for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study," Cancer 89(3):597-603 (Aug. 2000). cited by applicant .
Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," J. Biol. Chem., 267(11):7402-7405 (1992). cited by applicant .
Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom," J. Biol. Chem., 265(33):20259-20262 (1990). cited by applicant .
Eppstein et al., "Biological activity of liposome-encapsulated murine interferon .gamma. is mediated by a cell membrane receptor," PNAS USA 82:3688-3692 (1985). cited by applicant .
Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," Proc.-Conf. Colloid Chem. 193-196 (1993). cited by applicant .
Fang et al., "The impact of baseline liver histology on virologic response to interferon .alpha.-2b.+-.p ribavirin therapy in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572). cited by applicant .
Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," J. Nutritional Biochem. 4(1):630-634 (1993). cited by applicant .
Ferenci et al, "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977). cited by applicant .
Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon .alpha.," Lancet 356(9223):41 (Jul. 2000). cited by applicant .
Franchetti et al., "Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," J. Medicinal Chem. 38(19):3829-3837 (1995). cited by applicant .
Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001). cited by applicant .
Fujii et al., "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)," Int'l J. Pharmaceutics 234(1-2):121-128 (2002). cited by applicant .
Luft et al., "Electro-osmotic valve for the controlled administration of drugs," Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract). cited by applicant .
Gan to Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract). cited by applicant .
Gappa et al., "Juvenile laryngeal papillomatosis--a case report," Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract). cited by applicant .
Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996). cited by applicant .
Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Diabetologia 27:599-600 (1984). cited by applicant .
Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C--safety, efficacy, and virological rationale," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571). cited by applicant .
Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells," J. Biol. Chem., 268(26):19650-19655 (1993). cited by applicant .
Gonzales et al., "Randomized controlled trial including an initial 4-week `induction` period during one year of high-dose interferon .alpha.-2B treatment for chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975). cited by applicant .
Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha," Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995). cited by applicant .
Grant et al., "Combination therapy with interferon-.alpha. plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," J. Med. Virol. 61(4):439-442 (Aug. 2000). cited by applicant .
Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," N. Engl. J. Med., 326(20):1316-1322 (1992). cited by applicant .
Hageman, "The Role of Moisture in Protein Stability," Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988). cited by applicant .
Heathcote et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," New England J. Med. 343(23):1673-1680 (2000). cited by applicant .
Heim et al., "Intracellular signaling and antiviral effects of interferons," Dig. Liver Dis. 32(3):257-263 (Apr. 2000). cited by applicant .
Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," Endocrinol., 115:2176-2181 (1984). cited by applicant .
Hellstrand et al., "Histamine and cytokine therapy," Acta Oncol. 37(4):347-353 (1998). cited by applicant .
Hellstrand et al., "Histamine and the response to IFN-.alpha. in chronic hepatitis C," Interferon Cytokine Res. 18(1):21-22 (Jan. 1998). cited by applicant .
Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994). cited by applicant .
Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," J. Toxicol. Sci., 18(3):1-9 (1993). cited by applicant .
Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," International Journal of Pharmaceutics, 146(1):81-92 (1997). cited by applicant .
Hoffmann-La Roche Inc., Pegasys.RTM. (peginterferon alfa-2a), 15 pages (2002). cited by applicant .
Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999). cited by applicant .
Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia 11 Suppl 5:S47-S51 (Dec. 1997). cited by applicant .
Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," Am. J. Clin. Oncol. 18(1):27-31 (1995). cited by applicant .
IFNB Multiple Sclerosis Study Group, "Interferon.beta.-1b is effective in relapsing-remitting multiple sclerosis," Neurology 43(4):655-667 (Apr. 1993). cited by applicant .
Intermune.RTM. Inc., Infergen.RTM. (Interferon alfacon-1), 5 pages (2002). cited by applicant .
"Introduction to Antibodies", http://www.chemicon.com/resource/ANT101/al.asp, 8 pages (retrieved May 2, 2007). cited by applicant .
Isaacs et al., "Virus interference. I. The interferon," Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957). cited by applicant .
Jain et al., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," J. Microencapsulation 17(3):343-362 (2000). cited by applicant .
Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," The Oncologist 12(9):1143-1150 (2007). cited by applicant .
Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only). cited by applicant .
Kabalnov et al., "Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability," Journal of Colloid and Interface Science 184(1):227-235 (1996). cited by applicant .
Khalili et al., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," Am. J. Gastroenterol. 95(5):1284-1289 (May 2000). cited by applicant .
Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970). cited by applicant .
Kirkwood et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," J. Clin. Oncol. 14(1):7-17 (1996). cited by applicant .
Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-.gamma.," Drug Des. Deliv. 6(3):157-0167 (Sep. 1990). cited by applicant .
Knepp et al, "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," J. Pharm. Sci. Tech. 50(3):163-171 (1996). cited by applicant .
Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures," Pharma. Res. 15(7):1090-1095 (1998). cited by applicant .
Knobler et al., "Systemic .alpha.-interferon therapy of multiple sclerosis," Neurology 34(10):1273-1279 (Oct. 1984). cited by applicant .
Kovacevic et al., "Treatment of chronic viral hepatitis B in using secondary membranoproliferative glomerulonephritis using recombinant .alpha.-2 interferon," Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract). cited by applicant .
Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon .beta.-1b therapy in patients with MS," Neurology 54(1):193-199 (Jan. 2000). cited by applicant .
Kronenberger et al., "Influence of interferon-.alpha. on CD82-expression in HCV-positive patients," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976). cited by applicant .
Krown et al., "Interferons and interferon inducers in cancer treatment," Semin. Oncol. 13(2):207-217 (1986). cited by applicant .
Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon-.omega.," J. Interferon Res. 14:57-59 (1994). cited by applicant .
Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon-.omega.-mediated inhibition of human immunodeficiency virus replication," J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996). cited by applicant .
Larsson, "Stability of emulsions formed by polar lipids," Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978). cited by applicant .
Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon--A treatment," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974). cited by applicant .
Lee, "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology 26: 89S-95S (Sep. 1997) (XP000981288). cited by applicant .
Lopez et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983). cited by applicant .
Lukaszewski et al., "Pegylated .alpha. interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," J. Virol. 74(11):5006-5015 (Jun. 2000). cited by applicant .
Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982). cited by applicant .
Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," J. Pharm. & Pharmacol. 49(1):16-21 (1997). cited by applicant .
Magnuson et al. "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," Protein Expression & Purification 7:220-228 (1996). cited by applicant .
Malley et al., "Chronic Toxicity And Oncogenicity Of N-Methylpyrrolidone (Nmp) In Rats And Mice By Dietary Administration," Drug Chem Toxicol. 24(4):315-38 (Nov. 2001). cited by applicant .
Manning et al, "Stability of protein pharmaceuticals," Pharm. Res. 6(11):903-918 (1989). cited by applicant .
Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965). cited by applicant .
Massey, "Interaction of vitamin E with saturated phospholipid bilayers," Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982). cited by applicant .
McHutchison et al., "Interferon .beta.-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998). cited by applicant .
McHutchison et al., "Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment," Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only). cited by applicant .
Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006). cited by applicant .
Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-.alpha. plus IL-2 and IL-12)," J. Immunother. 23(3):369-378 (May-Jun. 2000). cited by applicant .
Milella et al., "Neutralizing antibodies to recombinant .alpha.-interferon and response to therapy in chronic hepatitis C infection," Liver 13(3):146-150 (Jun. 1993). cited by applicant .
Mohler, "Primer on electrodeposited coatings," Materials Engineering 5:38-45 (1972). cited by applicant .
Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," Int. J. Peptide Protein Research, 40:333-343 (1992). cited by applicant .
Morgan, "Structure and Moisture Permeability of Film-Forming Poloyers," Ind. Eng. Chem. 45(10):2296-2306 (1953). cited by applicant .
Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," J. Clinical Oncol. 19(5):1312-1319 (2001). cited by applicant .
Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," Diabet. Med., 15(11):937-945(1998). cited by applicant .
Neumann et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," Science 282:103-107 (Dec. 1998). cited by applicant .
Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-.alpha.-2a and a polyethylene glycol-modified derivative in healthy subjects," Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996). cited by applicant .
Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration," Eur. J. Pharm. Sci. 13(4):393-401 (2001). cited by applicant .
Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract). cited by applicant .
Ortiz et al., "A differential scanning calorimetry study of the interaction of .alpha.-tocopherol with mixtures of phospholipids," Biochim et Biophys Acta 898(2):214-222 (1987). cited by applicant .
Panitch, "Interferons in multiple sclerosis," Drugs 44(6):946-962 (Dec. 1992). cited by applicant .
Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," Nature, 282:260-266 (1979). cited by applicant .
Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," ILAR Journal, 32(3):16-19 (1990). cited by applicant .
Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed), pp. 456-458, Smith-Gordon, London (1990). cited by applicant .
Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973). cited by applicant .
Plauth et al, "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only). cited by applicant .
Plauth et al, "Open-label study of omega interferon in previously untreated HCV-infected patients," J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only). cited by applicant .
Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," J. Biol. Chem., 273(16):9778-9784 (1998). cited by applicant .
Poynard et al., "Is an `a la carte` combined interferon .alpha. 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," Hepatology 31(1):211-218 (Jan. 2000). cited by applicant .
Poynard et al., "Randomized trial of interferon .alpha. 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon .alpha. 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," Lancet 352(9138):1426-1432 (Oct. 1998). cited by applicant .
"Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD," Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release). cited by applicant .
Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., U. Tex. 487-495 (1987). cited by applicant .
Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," Pharm. Res. 14(2):119-127 (1997). cited by applicant .
Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma," Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998). cited by applicant .
Roche Pharmaceuticals, Roferon.RTM.-A (Interferon alfa-2a, recombinant), 22 pages (2003). cited by applicant .
Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971). cited by applicant .
Rogers et al., "Permeability Valves," Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957). cited by applicant .
Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," Transplantation 48(4):554-558 (1989). cited by applicant .
Roth et al., "High Dose Etretinate and Interferon-alpha--A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," Acta Oncol. 38(5):613-617 (1999). cited by applicant .
Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," Endocrinol. 148(12):6054-61 (Dec. 2007). cited by applicant .
Schepp et al., "Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2," Eur. J. Pharmacol., 269(2):183-191 (1994). cited by applicant .
Schering Corp., Intron.RTM. A for Injection, 6 pages (2001). cited by applicant .
Schering Corp., PEG-Intron.TM. (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003). cited by applicant .
Schmalfub et al., "Modification of drug penetration into human skin using microemulsions," J. Controlled Release 46(3):279-285 (1997). cited by applicant .
Sen et al., "The interferon system: a bird's eye view of its biochemistry," J. Biol. Chem. 267(8):5017-5020 (Mar. 1992). cited by applicant .
Shiffman et al., "A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567). cited by applicant .
Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000). cited by applicant .
Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," Ann. Int. Med. 132(7):517-524 (Apr. 2000). cited by applicant .
Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon .beta.1a," Neurology 55(2):185-192 (Jul. 2000). cited by applicant .
Sparks et al., "Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," Metabolism, 47(11):1315-1324 (1998). cited by applicant .
Sulkowski et al., "Pegylated Interferon Alfa-2A (Pegasys.TM.) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study," Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236). cited by applicant .
Sulkowski et al., "Peginterferon-.alpha.-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," Biodrugs 16(2):105-109 (2002). cited by applicant .
Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," Blood 98(6):1708-1713 (2001). cited by applicant .
Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," Endocrinology 146(9):3748-56 ( Sep. 2005). cited by applicant .
Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," Int. J. Cancer 87(5):741-749 (Sep. 2000). cited by applicant .
Tong et al., "Prediction of response during interferon .alpha. 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," Hepatology 26(6):1640-01645 (Dec. 1997). cited by applicant .
Touza Rey et al., "The clinical response to interferon-.gamma. in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus," Ann. Med. Int. 17(2):86-87 (Feb. 2000). cited by applicant .
Trudeau et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," Cancer Chemother. Pharmacol. 35(6):496-500 (1995). cited by applicant .
Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," PNAS USA, 90(5):1992-1996 (1993). cited by applicant .
Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," J. Pharm. Sci. 86(5):603-7 (May 1997). cited by applicant .
Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006). cited by applicant .
Vokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest," Cancer Chemother. Pharmacol. 35(4):304-312 (1995). cited by applicant .
Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998). cited by applicant .
Wang et al., "Preferential interaction of .alpha.-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," Eur. J. Biochem. 267(21):6362-6368 (2000). cited by applicant .
Wang et al., "Ripple phases induced by .alpha.-tocopherol in saturated diacylphosphatidylcholines," Archives of Biochem. & Biophys. 377(2):304-314 (2000). cited by applicant .
Wang et al., "The distribution of .alpha.-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine," Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000). cited by applicant .
Wang et al, "Parenteral formulations of proteins and peptides: stability and stabilizers," J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988). cited by applicant .
Weinstock-Guttman et al., "What is new in the treatment of multiple sclerosis?" Drugs 59(3):401-410 (Mar. 2000). cited by applicant .
Weissmann et al., "The interferon genes," Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986). cited by applicant .
Wright et al., "Preliminary experience with .alpha.-2b-interferon therapy of viral hepatitis in liver allograft recipients," Transplantation 53(1):121-123 (Jan. 1992). cited by applicant .
Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)," Diabetes, 48(5):1026-1034 (1999). cited by applicant .
Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with .alpha. interferons, in the treatment of chronic hepatitis C," Semin. Liver Dis. 19(Supp. 1):95-102 (1999). cited by applicant .
Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," J. Pharm. Sci. 85(4):396-401 (1996). cited by applicant .
Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine," Antivir. Res. 11(3):147-0160 (Apr. 1989). cited by applicant .
Zein, "Interferons in the management of viral hepatitis," Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998). cited by applicant .
Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," New Engl. J. Med. 343(23):1666-1672 (2000). cited by applicant .
Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon .alpha. on viral turnover," Hepatology 28(1):245-252 (Jul. 1998). cited by applicant .
Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," J. Clinical Pediatrics 14(2):83-84 (1996). cited by applicant .
Zhang et al, "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor," Pharm. Res. 12(10):1447-1452 (1995). cited by applicant .
Zheng et al. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," Beijing Med. J. 13(2):80-81 (1998). cited by applicant .
Ziesche et al., "A preliminary study of long-term treatment with interferon .gamma.-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," New Engl. J. Med. 341(17):1264-1269 (Oct. 1999). cited by applicant .
Sanofi-Aventis U.S. LLC, Prescribing Information for ADLYXIN.RTM. (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages. cited by applicant .
Amylin Pharmaceuticals, Inc., Prescribing Information for BYETTA.RTM. (Exenatide) Injection, rev. Oct. 2009, 34 pages. cited by applicant .
Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon.RTM. (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages. cited by applicant .
Novo Nordisk A/S, Prescribing Information for Victoza.RTM. (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages. cited by applicant .
Glaxosmithkline LLC, Prescribing Information for Tanzeum.RTM. (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages. cited by applicant .
Eli Lilly & Company, Prescribing Information for Trulicity.RTM. (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages. cited by applicant .
Adolf, "Human interferon omega-a review," Mult. Sclr. 1:S44-47 (1995). cited by applicant .
Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," J. Pharm. Sci. 91:388-395 (2002). cited by applicant .
Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros.RTM. device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010). cited by applicant .
Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984). cited by applicant .
Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8):911-917 (1998). cited by applicant .
Johnson et al., "How interferons fight disease," Sci. Am. 270(5):68-75 (May 1994). cited by applicant .
Lublin et al., "Defining the clinical course of multiple sclerosis: results of an international survey," Neurology. 46:907-911 (1996). cited by applicant .
Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results," Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009). cited by applicant .
Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," Drug Discovery Today 10(10):703-710 (May 15, 2005). cited by applicant .
Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study," Acta. Neurol. Scand. 100:283-289 (1999). cited by applicant .
Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," Neurology 43:662-667 (1993). cited by applicant .
PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009). cited by applicant .
"Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1," NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release). cited by applicant .
Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," US Endocrinology 7(2):104-109 (2011). cited by applicant .
Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial," Diabetic Medicine 27(9):1024-1032 (Sep. 2010). cited by applicant .
Roberts et al., "The Evolution of the Type I Interferonsl," J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998). cited by applicant .
Rohloff et al., "Duros Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008). cited by applicant .
"Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope", http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012). cited by applicant .
Shire et al., "Challenges in the Development of High Protein Concentration Formulations," J. Pharm. Sci. 93:1390-1402 (2004). cited by applicant .
Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007). cited by applicant .
Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011). cited by applicant .
Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," Current Physician 2(12):45-46 (1997). cited by applicant .
Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," Rev. Diabet. Stud., 5(2):73-94 (2008). cited by applicant .
Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," Salud Publica Mex 55:462-468 (2013). cited by applicant .
Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116. cited by applicant .
Croxatto. "Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant." Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8. cited by applicant .
Implanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright .COPYRGT. 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016. cited by applicant .
Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright .COPYRGT. 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016. cited by applicant .
Probuphine_Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016. cited by applicant .
Glumetza Brochure 2009, 13 Pages. cited by applicant .
Erowid,"Introduction to the Federal Controlled Substance Analog Act" 2001, 4 pages. cited by applicant .
Li et al. ("Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010. cited by applicant .
Palmeri et al., "5-Fluorouracil and recombinant .beta.-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327330 (Oct. 1990). cited by applicant .
Akers, et al., "Formulation Design and Development of Parenteral Suspensions," Journal of Parenteral Science & Technology, 41(3): 88-96 (1987). cited by applicant .
Alonso, et al., "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," Pharmaceutical Research, 10(7):945-953 (1993). cited by applicant .
Beck, et al., "Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive," Biology of Reproduction, 28(1): 186-195 (1983). cited by applicant .
Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988). cited by applicant .
Cha and Pitt, "A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules," Journal of Controlled Release, 7: 69-78 (1988). cited by applicant .
Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," Journal of Controlled Release, 8: 259-265 (1989). cited by applicant .
Cohen, et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," Pharmaceutical Research, 8(6): 713-720 (1991). cited by applicant .
Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," Journal of Microencapsulation, 9(2): 153-166 (1992). cited by applicant .
Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953). cited by applicant .
Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990). cited by applicant .
Lee and Timasheff, "The stabilization of proteins by sucrose," J. Biological Chem., 256(14): 7193-7201 (Jul. 1981). cited by applicant .
Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," Journal of Controlled Release, 37: 199-214 (1995). cited by applicant .
Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996). cited by applicant .
Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," Journal of Controlled Release, 3: 103-117 (1986). cited by applicant .
Mehta, et al.,"Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)," Journal of Controlled Release, 41: 249-257 (1996). cited by applicant .
Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," Pharmaceutical Research, 13(3): 360-367 (1996). cited by applicant .
Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," Pharmaceutical Research, 5(1): 21-30 (1988). cited by applicant .
Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," Endocrinology, 141(6): 1936-1941 (2000). cited by applicant .
Thomasin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996). cited by applicant .
Van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997). cited by applicant .
Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro." Biomaterials. 20(11:): 1057-1062 (1999). cited by applicant .
Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," Vaccine 14(9):879-885.(1996). cited by applicant .
Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," Journal of Controlled Release 43(1):9-22 (1997). cited by applicant.

Primary Examiner: Simmons; Ian
Assistant Examiner: Johnson; Karra S
Attorney, Agent or Firm: Moriarty; Gordon R. Trinque; Brian C. Lathrop Gage LLP

Description



FIG. 1 is a perspective view of our design for an implant placement guide.

FIG. 2 is a first side view of the design for the implant placement guide of FIG. 1;

FIG. 3 is a second side view of the design for the implant placement guide of FIG. 1;

FIG. 4 is a front view of the design for the implant placement guide of FIG. 1;

FIG. 5 is a back view of the design for the implant placement guide of FIG. 1;

FIG. 6 is a top view for the design for the implant placement guide of FIG. 1; and,

FIG. 7 is a bottom view for the design of the implant placement guide of FIG. 1.

The broken lines shown are included for the purpose of illustrating portions of the implant placement guide that form no part of the claim.

* * * * *

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.